The HOPE study and diabetes

微量白蛋白尿 雷米普利 医学 糖尿病 肾病 疾病 内科学 2型糖尿病 2型糖尿病 蛋白尿 内分泌学 血压
作者
Tonny Jensen
出处
期刊:The Lancet [Elsevier BV]
卷期号:355 (9210): 1181-1181 被引量:5
标识
DOI:10.1016/s0140-6736(00)02076-6
摘要

The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators (Jan 22, p 253)1Heart Outcomes Prevention Evaluation (HOPE) Study InvestigatorsEffects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy.Lancet. 2000; 355: 253-259Summary Full Text Full Text PDF PubMed Scopus (3298) Google Scholar report that ramipril given to people with diabetes mellitus lowered the risk of major cardiovascular outcomes by 25–30%. They claim that the effect was apparent irrespective of whether participants had a history of cardiovascular events, hypertension, or microalbuminuria, were taking insulin or oral hypoglycaemic agents, or had type-1 or type-2 diabetes mellitus. The investigators also state that ramipril lowered the risk of overt nephropathy, renal failure, or laser therapy, and that it had no long-term effect on glycaemic control. Although these results are interesting, several critical points can be raised, and it can also be argued that the new information given in the paper is limited. Figure 2 shows that the relative risk reduction in subgroups without microalbuminuria, with no cardiovascular disease and with type-1 diabetes do not reach significance despite high numbers of patients: without microalbuminuria (n=2437) and with no cardiovascular disease (n=1119). Since more than 98% of the patients had type-2 diabetes mellitus it is obvious that no conclusions of the effect of ramipril in type-1 diabetes mellitus can be drawn from the study. Thus, only in patients with diabetes with microalbuminuria or cardiovascular disease, or both, at high risk of having cardiovascular events, is the relative risk reduction significant. No data on metabolic control and blood pressure as absolute figures are given in the paper. We are only told that blood pressure and glycated haemoglobin (HbA1c) are significantly lower in the ramipril group, but for HbA1c the difference is not shown. Thus, it can be argued that the findings in this study only confirm what has been shown in the UK Prospective Diabetes Study.2UK Prospective Diabetes Study (UKPDS) GroupEfficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39.BMJ. 1998; 317: 713-720Crossref PubMed Google Scholar In the conclusion the investigators claim that ramipril lowered the risk of nephropathy, renal failure, or laser therapy. Ramipril does indeed reduce the risk of developing nephropathy in patients with microalbuminuria, as previous studies have shown.3Ravid M Lang R Rachmani R Lishner M Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus: a 7 year follow-up study.Arch Intern Med. 1996; 156: 286-289Crossref PubMed Scopus (0) Google Scholar However, table 3 shows that there was no effect on laser therapy (p=0·70) nor dialysis (p=0·70) in the ramipril group. The results of the HOPE study in patients with diabetes mellitus are important but mostly because they confirm previous studies. The study underlines the importance of strict metabolic control and aggressive antihypertensive treatment in high-risk patients with type-2 diabetes who have cardiovascular disease or microalbuminuria. However, it is not shown that patients with uncomplicated type-2 diabetes, with only one additional risk factor, will benefit from angiotensin-convertingenzyme (ACE) inhibitor treatment. Nor is it shown that there are new effects of ACE-inhibitors on end-stage manifestations of diabetic nephropathy or proliferative retinopathy. The HOPE study and diabetesAuthors' reply Full-Text PDF
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
fufufu123完成签到 ,获得积分10
4秒前
开心的大娘完成签到,获得积分10
4秒前
www完成签到 ,获得积分10
6秒前
末末完成签到 ,获得积分10
16秒前
无为完成签到 ,获得积分10
17秒前
白嫖论文完成签到 ,获得积分10
19秒前
上官若男应助忧伤的步美采纳,获得10
22秒前
科研通AI2S应助科研通管家采纳,获得10
22秒前
25秒前
从心随缘完成签到 ,获得积分10
26秒前
花花发布了新的文献求助10
28秒前
牛奶面包完成签到 ,获得积分10
29秒前
30秒前
岁月如歌完成签到 ,获得积分0
30秒前
33秒前
Li完成签到,获得积分10
35秒前
张琨完成签到 ,获得积分10
35秒前
35秒前
sunnyqqz完成签到,获得积分10
38秒前
热情的乘风完成签到,获得积分20
38秒前
40秒前
霍凡白完成签到,获得积分10
41秒前
42秒前
Feng发布了新的文献求助20
43秒前
怕孤单的若颜完成签到 ,获得积分10
45秒前
46秒前
ruochenzu发布了新的文献求助10
49秒前
zhongu发布了新的文献求助10
53秒前
阳光彩虹小白马完成签到 ,获得积分10
53秒前
Feng完成签到,获得积分10
55秒前
花花完成签到,获得积分10
57秒前
1分钟前
量子星尘发布了新的文献求助10
1分钟前
杨一完成签到 ,获得积分10
1分钟前
猫猫头完成签到 ,获得积分10
1分钟前
1分钟前
1分钟前
忒寒碜完成签到,获得积分10
1分钟前
1分钟前
XU博士完成签到,获得积分10
1分钟前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038039
求助须知:如何正确求助?哪些是违规求助? 3575756
关于积分的说明 11373782
捐赠科研通 3305574
什么是DOI,文献DOI怎么找? 1819239
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022